Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-FF58 |
| Synonyms | |
| Therapy Description |
177Lu-FF58 is a radioconjugate comprising a non-RGD small molecule that targets integrins alphaVbeta3 and alphaVbeta5 conjugated to the radionuclide lutetium-177, which delivers beta radiation to tumor cells expressing integrin alphaVbeta3 or alphaVbeta5, potentially resulting in antitumor activity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-FF58 | 177LuFF58|[177Lu]-FF58|Lutetium Lu 177 FF58 | 177Lu-FF58 is a radioconjugate comprising a non-RGD small molecule that targets integrins alphaVbeta3 and alphaVbeta5 conjugated to the radionuclide lutetium-177, which delivers beta radiation to tumor cells expressing integrin alphaVbeta3 or alphaVbeta5, potentially resulting in antitumor activity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05977322 | Phase I | 177Lu-FF58 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Terminated | NLD | ISR | ESP | CHE | 0 |